期刊文献+

LC-MS/MS法测定Beagle犬血浆中右旋酮洛芬的浓度 被引量:1

LC-MS/MS determination of dexketoprofen in Beagle dog plasma
原文传递
导出
摘要 目的:建立LC-MS/MS法测定Beagle犬血浆中右旋酮洛芬的浓度。方法:血浆样品采用乙腈沉淀法处理,取上清液进样。以乙腈(每500 mL中加入甲酸10μL)-水(80∶20,v/v)为流动相;用Zorbax Eclipse SB-C18柱(5μm,150 mm×4.6 mm)色谱柱分离;以布洛芬为内标。流速0.5 mL·min-1;进样量25μL;柱温为室温。质谱检测采用ESI正离子模式,扫描方式为多反应监测,扫描离子对m/z右旋酮洛芬253.0/209.0,布洛芬204.8/160.8。结果:右旋酮洛芬的线性范围为1.0~1000 ng·mL-1,线性关系良好(r=0.9979),最低定量下限为1.0 ng·mL-1,绝对回收率在100.0%~104.3%之间,变异系数均小于6%。结论:该方法预处理快速简单,灵敏度高,所建立的LC-MS/MS法准确、可靠,可用于犬血浆中右旋酮洛芬的浓度测定及药代动力学研究。 Objective :To establish an LC - MS/MS method for determination of dexketoprofen in beagle dog plasma. Methods:The plasma samples were deposited by acetonitrile before analysis. 25 uL supernatant was performed on a Zorbax Eclipse SB -C18 analytical column (5 um,150 mm ×4.6 mm) using acetonitrile (10 uL formic acid per 500 mL acetonitrile) -water (80: 20,v/v) as the mobile phase. The flow rate was 0.5 mL ·min-1. The mass spectrometer was operated under the positive ionmode and multiple reaction monitoring with the transitions of m/z 253.0/209.0 and m/z 204. 8/160. 8 was used to qualify dexketoprofen and ibuprofen (internalstandard),respectively. Results:The linear calibration curve was obtained in the range of 1.0 - 1000 ng· mL-1. The lower limit of quantification was 1.0 ng · mL-1. Accuracy in the mesurement of quality control samples were in the range of 100.0% -104. 3%. Conclusion:This method is simple, rapid and sensitive and can be used for determination of dexketoprofen in Beagle dogs plasma and pharmacokinetical study.
出处 《药物分析杂志》 CAS CSCD 北大核心 2011年第4期717-720,共4页 Chinese Journal of Pharmaceutical Analysis
关键词 酮洛芬 右旋酮洛芬 BEAGLE犬 液相色谱串联质谱 药代动力学 ketoprofen dexketoprofen Beagle dogs HPLC - MS/MS pharmacokinetics
  • 相关文献

参考文献7

二级参考文献24

  • 1陈亮,何凤慈,孟德胜.血浆中右旋酮洛芬的HPLC测定[J].中国药学杂志,2004,39(12):934-935. 被引量:3
  • 2管潇,张梦军,邬晓薇,张惠静.HPLC法测定人血浆中右旋酮洛芬的浓度[J].中国药师,2006,9(6):540-541. 被引量:2
  • 3Cordero JA. A comparative study of the transdermal penetration of a series ofnonsteroidal antiinflamatory drugs [J]. J P Harm Sci., 1997, 86:503-510.
  • 4Thacharodi D, Rao K P. Transdermal absorption of nifedipine from microemulsions of lipophilic skin penetration enhancers [J]. lnt J Pharm, 1994, 111 (3): 235-241.
  • 5Alvarez Fig Ueroa MJ, Blanco Mendezj. Tansdermal delivery of methotrexate: iontopphoretie delivery from hydrogels and passive delivery from microemulsion[J ]. Int J Pharm, 2001, 215 (1-2): 57-65.
  • 6Kreilgaard M, Erikj P, Jaroszewski JW. NMR characterization and transdermal drug delivery potential of microemulsion systems [J]. J Controlled Release, 2000, 69 (3): 421-433.
  • 7Schmalfub U, Neubert R, Wohlrab W. Modification of drug penetration into human skin using microemulsion[J]. J Control Rel, 1997, 46: 279-285.
  • 8Zimmermann KC, Sarbia M, Weber AA, et al. Cycloxygenase-2 expression in human esophageal carcinoma[J]. Cancer Res, 1999,59:198-204
  • 9Sheng H,Shao J,Kirdland SC, et al. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2[J]. J Clin Invest, 1997,51:1124
  • 10Graham D Y. Prevenyion of gastroduodenal injury induced by nonsteroidal antiinflanatory drug therapy[J]. Gastroenterology, 1999,96:675

共引文献52

同被引文献14

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部